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Background. Personalised medicine, new discoveries, and studies on rare exposures or 
outcomes require large samples that are increasingly difficult for any single investigator to 
obtain. Collaborative work is limited by heterogeneities, both what is being collected, and 
how it is defined.  
Objective. To develop a core set for data collection in rheumatoid arthritis (RA) research 
which (i) allows harmonization of data collection in future observational studies, (ii) acts as a 
common data model against which existing databases can be mapped, and (iii) serves as a 
template for standardized data collection in routine clinical practice to support generation of 
research-quality data. 
Methods. A multi-step, international multi-stakeholder consensus process was carried out 
involving voting via online surveys and two face-to-face meetings. 
Results. A core set of 21 items (“what to collect”) and their instruments (“how to collect”) 
was agreed: Age, gender, disease duration, diagnosis of RA, BMI, smoking, swollen/tender 
joints, patient/evaluator global, pain, quality of life, function, composite scores, acute phase 
reactants, serology, structural damage, treatment and comorbidities. 
Conclusions. The core set should facilitate collaborative research, allow for comparisons 





Research questions of the current era require ever larger study populations which often exceed 
the number of patients available in individual studies or registries, hence combined or pooled 
analyses are often required. Such collaborative work is, however, compromised by 
heterogeneities in the data collected. (1) More recently, routinely collected data from 
electronic medical records (EMR) has the potential to support research, but there is no agreed 
set of data that would be desirable to collect in order to generate research-quality data if used 
beyond direct clinical care. 
  
To facilitate collaborative research, standardizing items (“what to collect”) and their 
instruments (“how to collect”) across studies and data collections is critical. Although 
guidelines on data reporting and outcome measures have been developed, such core sets have 
so far pertained to randomized control trials and trial extension studies in rheumatoid arthritis 
(RA) (2, 3), and have not been vetted against the feasibility of data collection in routine 
clinical care, nor against the needs of observational research. Indeed, any core dataset to be 
implemented in registers, research cohorts or EMR systems need to strike a balance between 
clinical feasibility and the potential to generate useful, research-quality data. 
 
For these reasons, a EULAR task force was convened to develop a standardised core set for 
data collection in RA that should (i) harmonize data collection in future observational studies, 
(ii) act as a common data model against which existing databases and EMR systems can be 
mapped, and (iii) ensure that new data collections in routine clinical practice can support the 




The task force comprised a steering committee (n=10, including 2 co-conveners (WD, JA), a 
EULAR methodologist (LG), a patient partner (CZ) and 3 fellows (HR, KC, EN)), a working 
group (additional 15 experts from 11 European countries and the U.S. including patients, 
clinical researchers and experts in the area of epidemiology, quality of care, and common data 
modelling, physicians and other health professionals), and a pan-European expert panel 
(n=90).  
 
The task force employed a step-wise process (figure 1) in accordance with the EULAR 
standard operating procedure (4), underpinned by an inventory of data collection in existing 
RA clinical cohorts and registers (1):  
  
(a) An hierarchical literature review was carried out by the fellows in PubMed to identify data 
items and instruments used in existing RA registers and clinical cohorts, and the frequency 
with which these items and instruments were collected. Results were cross-checked with 
EULAR recommendations for reporting in RA clinical trials and trial extension studies (2, 3) 
and with the EULAR outcome measures library. Items and instruments felt to be missing 
could be added by the steering committee.  
 
(b) In an online survey, the expert panel rated the perceived importance of each of the above 
items (and instruments) to be included in a core set, using a grading scale from 1 (not 
important) to 9 (very important). Again, items and instruments could be added.  
 
(c) At the first face-to-face meeting of the working group, electronic voting on individual 
items and instruments to include in the core set took place. We defined consensus as >70% of 
participants voting either YES or NO to the inclusion of a given item; if no consensus was 
reached, a second vote took place after a brief discussion which was led by an independent 
moderator (DP). In this second round, the threshold for consensus was lowered to 60%. The 
resultant list of items that had reached consensus for inclusion informed a single round of 
voting on the instruments with which to collect information on the items.  
 
(d) Additional information on items and instruments for which no consensus was reached was 
collected. Ratification of items included, reasons for any exclusion, and voting on items that 
had not reached consensus at the face-to-face meeting was performed via an online survey 
within the working group.  
 
(e) At the second face-to-face meeting of the working group, voting was conducted for 
outstanding items, then for final approval of the complete core list of items, followed by 
voting on instruments for all items in the final list using the same method of moderated 
discussion and voting cut-offs as outlined above. 
 
In all voting processes, the panellists were reminded of the importance of striking a balance 





(a) Literature review 
Published articles from 67 different European RA registers and clinical cohorts were included. 
In total, 39 items and 125 instruments were identified; 8 additional items for consideration 
were added (supplementary table 1 and 2).  
 
(b) Online survey 
90 experts from 28 different European countries including patients (18%), allied health 
professionals (18%), physicians (55%) and researchers (10%) participated in the survey. 29 of 
the 47 proposed items were considered important enough for inclusion into a core set 
(supplementary table 2). 
 
(c) First face-to-face meeting  
21/25 (84%) members attended. In the first voting round consensus for inclusion was reached 
for 16/47 (34%) items, and consensus for exclusion for 16/47 (34%) items. After discussion 
and a second round of voting on the remaining 15 items, consensus was reached for inclusion 
of 5 and for exclusion of 7, leaving two items (“health related quality of life”, and 
“socioeconomic status”) without consensus (supplementary table 2).  
 
(d) Online ratification 
23/25 (92%) members participated. The voting results from the face-to-face meeting were 
confirmed except for socioeconomic status, health-related quality of life, fatigue, and joint 
surgery (lack of consensus). 
 
(e) Second face-to-face meeting  
17/25 (68%) members attended. Voting led to the exclusion of items “fatigue”, “joint surgery” 
and “socioeconomic status” but inclusion of “health-related quality of life”. Next, the 
resultant set of the remaining 21 items was voted on in its entirety, and 100% of the 
participants agreed (Table 1). Moderated discussion and sequential voting on the instruments 
with which to collect these 21 items resulted in consensus for all but two instruments (how to 
collect data for items “glucocorticoids”, and “comorbidity”). 
 
(f) Second online survey 
A final ad hoc online survey with pre-specified suggestions provided by the steering 
committee for the outstanding instruments for items ‘glucocorticoids’ and ‘comorbidity’ was 
performed (supplementary table 3). 21/25 (84%) members participated, and consensus was 




BOX. Structure and content of the RA core set developed by the EULAR Task Force 
 
ITEM RECOMMENDATION OF STANDARDIZED WAY OF ASSESSMENT 
1) Age date of birth 
2) Gender male / female 
3) Disease duration date of diagnosis 
4) Diagnosis of RA Rheumatologist reported diagnosis of RA 
5) Body mass index (BMI) weight and height 
6) Smoking current / previous / never 
7) Tender joints 28 joint count 
8) Swollen joints 28 joint count 
9) Patient global 
measured on VAS or NRS scale capturing: 1) global assessment of disease 
activity; 2) related to arthritis; 3) today  
Example wording: “Considering all the ways your arthritis has affected you, 
how do you feel your arthritis is today?” anchors: excellent  - very poor  
10) Evaluator global 
measured on VAS or NRS scale capturing: 1) global assessment of disease 
activity; 2) related to arthritis; 3) today 
Example wording: ”What is your overall assessment of the patient's RA 
disease activity today?” anchors: excellent  - very poor 
11) Pain 
measured on VAS or NRS capturing: 1) pain; 2) related to arthritis; 3) last 
week 
Example wording: “How much pain did you have due to your arthritis last 
week?” anchors: no pain – worst imaginable pain 
12) Physical function Health Assessment Questionnaire (HAQ) 
13) Health related quality of life Euro-Qol 5 dimensions (EQ5D)*  
14) Composite Scores  
Collection of Core Items 7-12 and 15 enables to calculate following 
composite scores:  
- CDAI(Clinical disease activity index) 
- SDAI (Simplified disease activity index) 
- DAS28 (Disease activity Score 28 joints) 
- EULAR response criteria 
- ACR response criteria 
15) Acute phase reactants  C-reactive protein (CRP) AND erythrocyte sedimentation rate (ESR) 
16) Serology Rheumatoid factor (RF) AND anti-CCP antibodies (ACPA) 
17) Structural Damage  Presence of erosions on X-ray Yes/No 
18) DMARD History name of previous DMARD(s) (including biological, synthetic and targeted synthetic DMARDs 
19) Ongoing / most recent 
DMARD 
name of DMARD  
start and stop date  
reason for stopping  
20) Glucocorticoids  current use of oral glucocorticoids: 1) dose taken today __mg prednisolone equivalent; and 2) continuous (> 3 months) intake YES/NO 
21) Comorbidities 
binary assessment YES/NO of the six EULAR comorbidity domains 
(cardiovascular disease, malignancies, infections, gastrointestinal disease, 
osteoporosis, depression) (5) 







This EULAR taskforce has defined an RA core set, including both items and instruments to 
support standardised RA data collection in clinical practice and research. This will enable 
collaborative research studies, and increase comparability across studies.  
 
Unlike most previous core sets, this set was specifically developed keeping clinical feasibility 
in mind. Importantly, “core” underscores that the set represents a minimum, acknowledging 
that individual stakeholders are likely to add items or instruments of particular interest to their 
own data collection. 
 
Consensus for inclusion was straightforward for the majority of items: 16 of the final 21 items 
were agreed in the first round of voting. Six additional items were included, and after a 
ratification survey and discussion, ‘joint surgery’ was excluded in the subsequent process. 
Discussion for each item is summarized in supplementary table 3. Of the 26 items ultimately 
excluded from the core dataset 9 were seen as important by the expert group. One item, 
‘fatigue’, was excluded from our core dataset yet is present in the OMERACT core outcome 
set for RA trials.(6) Discussion during the meeting acknowledged that this item was important 
but depending on many factors unrelated to RA and can be captured by PGA. The group 
repeatedly revisited the scope of a core set, and agreed that fatigue was a good example of an 
item that might regularly be collected in addition to the core set for either clinical practice or 
research. 
 
The task-force was established to include expertise in registers and observational research, 
clinical practice, use of EMRs, the patient perspective, as well as methodological expertise in 
the development of core datasets (7) to enable robustness and transparency. To ensure 
inclusiveness, all national European rheumatology societies were invited to contribute. 
Dissemination of the core set will be facilitated by publication online (EULAR website) and 
via national societies.  
 
Following agreement on this core set, it is important that it is adopted by future observational 
data collections and research studies in RA. For EMR systems to deliver to RA research, the 
core set also needs to be integrated into EMR systems. Additional clinical benefits of 
collection of structured data such as informing consultations, viewing longitudinal disease 
progression, supporting audit, and benchmarking care quality (8) should be recognised and 
may encourage its clinical adoption. 
 
In summary, through a multi-step, multi-stakeholder, and evidence-based process, this task 
force has developed an RA core set that may (i) harmonize data collection in future 
observational studies, (ii) act as a common data model against which existing databases can 
be mapped, and (iii) serve as a template for standardized data collection in routine clinical 
practice to support the generation of research-quality data. This effort, which will continue to 
be updated and revised after evaluation of its implementation, may serve as an example for 
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